



Artisan Mid Cap Fund

MONTHLY
Commentary

Investor Class: ARTMX

Advisor Class: APDMX

As of 30 November 2020

Commentary

Global equity markets have surged higher so far in Q4, with November delivering the best single-month return in over 30 years. Several COVID-19 clinical trials have released analyses showing ~90% or greater effectiveness in preventing the disease, and a vaccine rollout is expected to commence over the near term. Energy, financials and industrials—sectors suffering the most in the depths of the pandemic—are leading, and health care, consumer staples and real estate, while positive, have lagged.

Our portfolio trails the Russell Midcap® Growth and Russell Midcap® Indices so far in Q4 though remains ahead of both indices YTD. Among our bottom contributors are DexCom and Zynga. Shares of DexCom have fallen on rising competitive concerns—particularly for its G7 product, which is expected to rollout in the second half of 2021. However, we believe the long-term trend toward the use of continuous glucose-monitoring devices for diabetes is in the early stages, and DexCom remains well-positioned to maintain share of this market over time.

Shares of Zynga have consolidated some of their solid YTD gains. With the capability to make additional opportunistic acquisitions and a solid pipeline of games under development, we believe the company's profit cycle remains in motion. We used recent weakness to add to our position.

Among our top contributors are BioNTech and Hubspot. BioNTech is a biotech company developing mRNA therapies with a focus on oncology. The company has partnered with Pfizer to develop a COVID-19 vaccine and recently announced an early analysis showing its drug to be more than 90% effective in protecting people from the virus. Given this development and the long-term value creation we expect in the company's cancer treatment pipeline, we believe the profit cycle ahead is compelling.

HubSpot is a developer and marketer of software products for inbound marketing, sales and customer service. The company has added new customers at a significantly faster rate than before the pandemic. It has never been more important for businesses to have an online presence, and HubSpot's solutions are instrumental in improving digital marketing efforts.

Our process is focused on identifying franchises exposed to accelerating profit cycles with reasonable valuations. It is our belief that owning companies with these characteristics should lead to outperformance over full market cycles. We will continue to adhere to this approach, regardless of the macro backdrop and how it evolves in the period ahead.

Portfolio Details

| | ARTMX | APDMX |
|-------------------------------------|-------------|------------|
| Net Asset Value (NAV) | \$45.26 | \$45.91 |
| Inception | 27 Jun 1997 | 1 Apr 2015 |
| Expense Ratios | | |
| Annual Report 30 Sep 2020 | 1.18% | 1.05% |
| Prospectus 30 Sep 2019 ¹ | 1.19% | 1.05% |

¹See prospectus for further details.

Top 10 Holdings (% of total portfolio)

| | |
|--|--------------|
| Global Payments Inc (Information Technology) | 4.8 |
| Atlassian Corp PLC (Information Technology) | 3.8 |
| Veeva Systems Inc (Health Care) | 3.4 |
| HubSpot Inc (Information Technology) | 2.9 |
| Genmab A/S (Health Care) | 2.7 |
| Match Group Inc (Communication Services) | 2.5 |
| Zynga Inc (Communication Services) | 2.4 |
| Exact Sciences Corp (Health Care) | 2.4 |
| Ascendis Pharma A/S (Health Care) | 2.3 |
| Catalent Inc (Health Care) | 2.3 |
| TOTAL | 29.5% |

Source: Artisan Partners/GICS.

Sector Diversification (% of total portfolio equities)

| | Fund | RMCG ¹ |
|------------------------|---------------|-------------------|
| Communication Services | 9.0 | 6.3 |
| Consumer Discretionary | 11.6 | 10.7 |
| Consumer Staples | 1.3 | 3.7 |
| Energy | 0.0 | 0.4 |
| Financials | 2.6 | 3.4 |
| Health Care | 26.2 | 22.2 |
| Industrials | 10.6 | 11.9 |
| Information Technology | 36.5 | 37.8 |
| Materials | 1.0 | 2.1 |
| Real Estate | 0.0 | 1.4 |
| Utilities | 1.1 | 0.1 |
| TOTAL | 100.0% | 100.0% |

Source: Artisan Partners/GICS/Russell. Cash and cash equivalents represented 2.4% of the total portfolio. ¹Russell Midcap® Growth Index.

Investment Results (%)

| As of 30 November 2020 | MTD | QTD | YTD | 1 Yr | 3 Yr | 5 Yr | 10 Yr | Inception |
|------------------------------|-------|-------|-------|-------|-------|-------|-------|-----------|
| Investor Class: ARTMX | 11.77 | 10.29 | 49.87 | 51.73 | 25.67 | 18.27 | 15.83 | 14.76 |
| Advisor Class: APDMX | 11.77 | 10.31 | 50.06 | 51.94 | 25.87 | 18.45 | 15.93 | 14.80 |
| Russell Midcap® Growth Index | 13.43 | 13.57 | 29.38 | 30.90 | 18.84 | 17.01 | 15.20 | 9.93 |
| Russell Midcap® Index | 13.82 | 14.55 | 11.86 | 14.43 | 10.26 | 11.75 | 12.65 | 10.00 |

As of 30 September 2020

| | | | | | | | | |
|------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| Investor Class: ARTMX | 1.29 | 11.91 | 35.89 | 45.66 | 22.86 | 17.59 | 15.57 | 14.39 |
| Advisor Class: APDMX | 1.30 | 11.95 | 36.03 | 45.83 | 23.05 | 17.77 | 15.67 | 14.43 |
| Russell Midcap® Growth Index | -1.40 | 9.37 | 13.92 | 23.23 | 16.23 | 15.53 | 14.55 | 9.40 |
| Russell Midcap® Index | -1.95 | 7.46 | -2.35 | 4.55 | 7.13 | 10.13 | 11.76 | 9.44 |

Source: Artisan Partners/Russell. Returns for periods less than one year are not annualized. Class inception: Investor (27 June 1997); Advisor (1 April 2015). For the period prior to inception, Advisor Class performance is the Investor Class's return for that period ("Linked Performance"). Linked Performance has not been restated to reflect expenses of the Advisor Class and the share class's returns during that period would be different if such expenses were reflected.

Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance.

Average Annual Total Returns

Market Cap Distribution (% of total portfolio equities)

| \$ in billions | Fund | RMCG ¹ |
|----------------|---------------|-------------------|
| 26.7+ | 41.9 | 41.5 |
| 20.6–26.7 | 10.7 | 10.5 |
| 14.3–20.6 | 20.5 | 20.3 |
| 8.8–14.3 | 20.1 | 17.3 |
| 0–8.8 | 6.6 | 10.3 |
| TOTAL | 100.0% | 100.0% |

Source: Artisan Partners/Russell. ¹Russell Midcap® Growth Index.

Team Leadership (Pictured left to right)



| Portfolio Managers | Years of Investment Experience |
|-----------------------------|--------------------------------|
| Matthew H. Kamm, CFA (Lead) | 21 |
| James D. Hamel, CFA | 24 |
| Craigh A. Cepukenas, CFA | 32 |
| Jason L. White, CFA | 20 |

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

Current and future portfolio holdings are subject to risk. International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period.

Russell Midcap® Growth Index measures the performance of US mid-cap companies with higher price/book ratios and forecasted growth values. Russell Midcap® Index measures the performance of roughly 800 US mid-cap companies. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 30 Nov 2020: BioNTech SE 1.1%; DexCom Inc 2.0%. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

Unless otherwise indicated, all information in this report includes all classes of shares, except performance and expense ratio information, and is as of the date shown in the upper right hand corner. Totals may not sum due to rounding.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

The Global Industry Classification Standard (GICS®) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

Frank Russell Company ("Russell") is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell's express written consent. Russell does not promote, sponsor or endorse the content of this communication.

Sector exposure percentages reflect sector designations as currently classified by GICS.

Our capital allocation process is designed to build position size according to our conviction. Portfolio holdings develop through three stages: GardenSM, CropSM and HarvestSM. GardenSM investments are situations where we believe we are right, but there is not clear evidence that the profit cycle has taken hold, so positions are small. CropSM investments are holdings where we have gained conviction in the company's profit cycle, so positions are larger. HarvestSM investments are holdings that have exceeded our estimate of intrinsic value or holdings where there is a deceleration in the company's profit cycle. HarvestSM investments are generally being reduced or sold from the portfolios.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2020 Artisan Partners. All rights reserved.

12/3/2020 A20769L_vR